Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Dopamine-Enhancing Therapies and Risk of Neovascular AMD Conversion: A Target Trial Emulation.

American journal of ophthalmology·2026

Same author

Longitudinal Trends of Intraocular Lens Dislocation in a Federated Electronic Health Record Network.

Ophthalmic surgery, lasers & imaging retina·2026

Same author

Efficacy of Continuous Pegcetacoplan Treatment for Subfoveal Geographic Atrophy in Age-Related Macular Degeneration: 36-Month Results from OAKS, DERBY, and GALE Open-Label Extension.

Clinical ophthalmology (Auckland, N.Z.)·2026

Same author

Prevalence and incidence of mental health disorders in patients with inherited retinal diseases: a population-based study.

Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus·2026

Same author

Association of Atopic Dermatitis with Retinal Detachment and Postoperative Proliferative Vitreoretinopathy Risk.

Ophthalmology. Retina·2026

Same author

Association Between Mental Health Disorders in Age-Related Macular Degeneration: A Cohort Study Using a Global Health Records Network.

Ophthalmic surgery, lasers & imaging retina·2026

Search research articles

Related Experiment Video

Updated: May 16, 2026

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Published on: June 14, 2021

Ocriplasmin for vitreoretinal diseases.

Irena Tsui¹, Carolyn K Pan, Ehsan Rahimy

¹Retina Division, Jules Stein Eye Institute, University of California, Los Angeles, CA 90095, USA. itsui@jsei.ucla.edu

Journal of Biomedicine & Biotechnology

|November 30, 2012

Summary

This summary is machine-generated.

Ocriplasmin, a novel ophthalmic medication, effectively cleaves fibronectin and laminin at the vitreoretinal interface. Clinical trials show promising results for treating vitreoretinal diseases, potentially improving patient outcomes.

More Related Videos

Intravitreal Injections in the Ovine Eye

Intravitreal Injections in the Ovine Eye

Published on: July 5, 2022

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye

Published on: March 30, 2020

Related Experiment Videos

Last Updated: May 16, 2026

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Published on: June 14, 2021

Intravitreal Injections in the Ovine Eye

Intravitreal Injections in the Ovine Eye

Published on: July 5, 2022

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye

Published on: March 30, 2020

Area of Science:

Ophthalmology
Molecular Biology
Pharmacology

Background:

Fibronectin and laminin are key proteins at the vitreoretinal interface.
These proteins are implicated in various vitreoretinal diseases.
Plasmin receptors play a crucial role in ocular tissue remodeling.

Purpose of the Study:

To evaluate the efficacy of ocriplasmin in cleaving fibronectin and laminin.
To assess the potential of ocriplasmin as a treatment for vitreoretinal diseases.
To investigate the impact of ocriplasmin on patient care for conditions like vitreomacular traction and macular hole.

Main Methods:

Clinical trials were conducted to study ocriplasmin.
Ocriplasmin's action on fibronectin and laminin was investigated.
Patient outcomes for specific vitreoretinal diseases were monitored.

Main Results:

Ocriplasmin demonstrated the ability to cleave fibronectin and laminin.
Clinical trials yielded promising results for ocriplasmin's therapeutic potential.
The medication showed potential in addressing vitreoretinal pathologies.

Conclusions:

Ocriplasmin is a novel ophthalmic medication targeting specific plasmin receptors in the eye.
Promising clinical trial results suggest ocriplasmin may significantly impact the management of vitreoretinal diseases.
Further research and application of ocriplasmin may lead to improved patient care.